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Transplant outcomes of patients receiving unrelated marrow grafts from CCR5 wild-type (1/1), CCR5D32 heterozygous (1/-) or
CCR5D32 homozygous (-/-) donors.
1/1 (n5 344) 1/- (n5 39) -/- (n5 8)
Grades II-IV 309 (90%) OR5 1 34 (87%) OR5 0.77 (0.28-2.10, P5.61) 6 (75%) OR5 0.34 (0.07-1.75, P5.20)
Grades III-IV 124 (36%) OR5 1 13 (33%) OR5 0.89 (0.44-1.79, P5.74) 1 (13%) OR5 0.25 (0.03-2.08, P5.20)
Skin 288 (84%) OR5 1 18 (46%) OR5 0.89 (0.37-2.11, P5.79) 4 (50%) OR5 0.19 (0.05-0.80, P5.02)
Liver 159 (46%) OR5 1 32 (82%) OR5 0.65 (0.33-1.30, P5.22) 2 (25%) OR5 0.39 (0.08-1.95, P5.25)
Gut 219 (64%) OR5 1 14 (36%) OR5 0.82 (0.42-1.61, P5.57) 5 (63%) OR5 0.95 (0.22-4.05, P5.95)
Chronic 207 (60%) HR5 1 19 (49%) HR5 0.96 (0.60-1.53, P5.85) 3 (38%) HR5 0.45 (0.14-1.41, P5.17)
Poster Session II S301Patients who received bone marrow from CCR5d32 homozygous
donors had lower risk of skin GVHD than the control group and the
difference is statistically significant. We screened our GVHD tissue
repository of allograft recipients, to select ten samples from skin and
lip that showed histological features of GVHD and had the most
abundant number of lymphocytes. We found that lymphocyte infil-
trates in all the samples were predominantly CCR5+ T cells. Approx-
imately 80% of CD4+ T cells in the skin and lip biopsies were
CCR5+ cells, whereas 70% of CD8+ T cells were CCR5+. Thus,
CCR5 expression was present on most CD4+ and CD8+ T cells in-
volved in the pathogenesis of skin GVHD. Using allogeneic DCs
mixed with responder PBMCs, we found CCR5 was upregulated
on the subpopulation of T cells that were actively dividing and had
acquired characteristics of activated T cells after allogeneic stimula-
tion. The majority of CCR5+ T cells were CD45RA-/CD45RO+
with decreased expression of CD62L and CD69. In addition, we
found that activated CD4+ T cells that produced cytokine TNFa,
IL-2 or IFN-g, were positive for CCR5. In addition, the TNFa
and IL-2 producing CD8+ T cells also expressed CCR5. This obser-
vation supported the notion that CCR5 is a marker for effector T
cells that actively participate in the ‘‘cytokine storm’’ of GVHD.
Our data demonstrated that CCR5+ T cells are important in mediat-
ing GVHD in human.389
OVER-EXPRESSION OF TRAIL ON DONOR T CELLS SIMULTANEOUSLY
AMELIORATES GVHD AND ENHANCES GVT
Ghosh, A.1, Holland, A.M.1, Kappel, L.W.1, Dogan, Y.2, Yim, N.1,
Rao, U.1, Smith, O.M.1, Jenq, R.R.1, Zakrzewski, J.1, Na, I.-K.1,
Lu, S.1, Tsai, J.1, Penack, O.1, Hanash, A.1, Sauer, M.G.3,
Sadelain, M.4, van den Brink, M.R.M.1 1Memorial Sloan-Kettering
Cancer Center, New York, NY; 2Memorial Sloan-Kettering Cancer Cen-
ter, New York, NY; 3Medizinische Hochschule Hannover, Hannover,
Germany; 4Memorial Sloan-Kettering Cancer Center, New York, NY
TNF-Related Apoptosis Inducing Ligand (TRAIL) is a type II
membrane protein, which can transduce apoptotic signals
through death receptor (DR) 4 and 5 molecules (only DR5 in
mice) expressed on target cells. Previous studies with TRAIL-
deficient donor T cells indicated that TRAIL is dispensable in
the development of lethal graft-versus-host disease (GVHD),
although it plays a role in thymic GVHD. In contrast,
TRAIL-deficient T cells displayed a significant loss in graft-ver-
sus-tumor (GVT) activity. In this study, we evaluated the effect
of TRAIL over-expression in donor T cells (mature and precur-
sor stage) on GVHD and GVT. Mature T cells derived from
donor splenocytes were transduced with a lentiviral TRAIL
expression vector. The transduced TRAIL+ cells were adoptively
transferred on day 0 into recipients of a T cell depleted alloge-
neic hematopoietic stem cell transplantation (TCD-AHSCT) to
assess their effects on GVHD and GVT. T cell precursors were
generated from murine hematopoietic stem cells, transduced
with lentiviral vectors and expanded using the OP9-DL1 co-cul-
ture system. Mature splenic TRAIL+ T cells were able to mount
significantly enhanced antitumor immunity compared to T cells
transduced with a control vector against tumor cell lines in vitro
and upon transfer into tumor bearing AHSCT recipients. To
our surprise, AHSCT recipients treated with TRAIL+ T cellshad significantly less GVHD. We observed increased DR5 ex-
pression on host antigen presenting cells (APC) soon after the
total body irradiation used in our preparative regimens, suggest-
ing that TRAIL+ donor T cells could eliminate host APC, re-
sulting in less GVHD. Finally, adoptive transfer of TRAIL+
precursor T cells could reconstitute the T cell compartment
and resulted in enhanced GVT activity without exacerbation
of GVHD. In conclusion, our data indicate that adoptive trans-
fer of TRAIL+ donor T cells or T cell precursors can enhance
GVT activity, while ameliorating GVHD possibly through the
elimination of host APC.390
LONG TERM SURVIVAL AND RELAPSE RATE AFTER TRANSPLANTATION
OF HIGHLY T AND B CELL DEPLETED STEM CELLS FROM ALTERNATIVE
DONORS IN PEDIATRIC PATIENTS WITH ACUTE LYMPHATIC LEUKEMIA
Lang, P.J.1, Mueller, I.1, Teltschik, H.-M.1, Schumm,M.1, Pfeiffer, M.1,
Feuchtinger, T.1, Greil, J.2, Bader, P.3, Klingebiel, T.3,
Handgretinger, R.1 1University Children’s Hospital, Tuebingen, Ger-
many; 2University Children’s Hospital, Heidelberg, Germany; 3Univer-
sity Children’s Hospital, Frankfurt, Germany
We present long term results in 68 children with ALL who
received highly T and B cell depleted stem cells from matched unre-
lated (n5 17) or full haplotype mismatched related donors (n5 51)
at our institution. Our aimwas tominimizeGvHDand to avoid EBV
LPD in both matched and mismatched transplantations. Remission
status was: CR1,n5 18; CR2,n5 23; $CR3,n5 12; non remission
or second transplant, n5 15. Graft manipulation was carried out
with microbeads and the CliniMACS device (indirect depletion
of T and B cells with CD34+ positive selection (n5 50); or direct
depletion with anti-CD3/anti-CD19 coated microbeads (n5 18)).
T andB cell counts were reduced for 4-5 log withmedian numbers
of residual T cells of 15 000/kg bw (CD34+ selection) and 49 000/kg
bw (CD3/19 depletion). No pharmacological immune suppression
was given after positive selection, whereas patients with CD3/19 de-
pletion received MMF. The conditioning regimens were either TBI
or Bu based (n5 50) or a toxicity reduced protocol (Flud, TT, Mel)
was used (n5 18). Rejection prophylaxis was carried out with ATG
orOKT3. Primary engraftment occurred in 85%. After recondition-
ing, final engraftment was achieved in 98%. GvHD grade 0-1 oc-
curred in 86%. 12% had grade II, 4% had grade III. Chronic
GvHD occurred in 4 patients. No GvHD related mortality was
observed. Median follow up was 5.9 years. EFS at 1 year was
56%(CR1), 51%(CR2) and 50%($CR3); EFS at 5 years was
49%(CR1), 46%(CR2) and 27%($CR3). Median survival of
patients with active disease was 0.2 years. Relapse rates at 1 year
were 0.32(CR1), 0.47(CR2) and 0.46($CR3); relapse rates at 5 years
were 0.32(CR1), 0.47(CR2) and 0.64($CR3). TRM at 1 year was
14%, causes of death remained viral and fungal infections, no EBV
LPD occurred.
Conclusions: positive selection of progenitor cells or depletion of T
and B cells can minimize acute and chronic GVHD in both matched
unrelated and mismatched related transplantations and may prevent
GvHD related mortality. Lethal infections occurred in 14% of the
patients probably due to the delayed recovery of T cells. Despite pro-
found depletion of donor T cells, relapse rates were acceptable and
remained on a stable level after the first year in patients with com-
plete remission. Thus, absence of GvHD may not necessarily be as-
sociated with high relapse rates in childhood ALL. Apart from T
S302 Poster Session IIcells, other effector cells like NK cells are likely to exert GvL effects
and may contribute to the favorable EFS of our patients.391
MEK INHIBITION RESULTS IN SELECTIVE IMMUNOSUPPRESSION OF
HUMAN T CELLS AND DECREASES CYTOKINE PRODUCTION IN A
MEMORY STAGE-DEPENDENT MANNER
Kim, T.K.1,2, Valencia Gattas, M.1, Benjamin, C.L.1, Levy, R.B1,
Wieder, E.D.1, Komanduri, K.V.1,2 1University of Miami Sylvester Can-
cer Center, Miami, FL; 2M.D. Anderson Cancer Center, Houston, TX
Although allogeneic stem cell transplantation is a treatment of
choice for many hematologic malignancies, a key complication is
graft-versus-host disease (GVHD). Although currently used immu-
nosuppressive medications may successfully inhibit GVHD, none
are selective enough to spare pathogen-specific T cells, leading to
an increased risk of life-threatening infections (e.g., CMV reactiva-
tion). Recent studies suggest that naive and early memory T cells
may be relatively more potent at inducing GVHD, whereas we and
others have shown that most CMV-specific T cells exist as relatively
differentiated cells. Therefore, we reasoned that differences in sig-
naling could be used to selectively inhibit certain maturation stages
of human T cells. Since the MAPK pathway has been demonstrated
to be important for cytokine production in T cells, we measured
phospho-Erk1/2 (p-Erk) in PMA:Ionomycin-treated or SEB-
stimulated CD4+ and CD8 +T cell maturation subsets by flow
cytometry. Naive (CD27 + CD45RA+) and early memory (M1,
CD27 + CD45RA-) T cells expressed three-fold higher p-Erk than
intermediate (M2, CD27-CD45RA-) and late memory (M3,
CD27-CD45RA+) T cells (P\0.05). To test the hypothesis that
the effects of MEK inhibition depend on p-Erk expression, we stim-
ulated T cells from healthy donors using allogeneic dendritic cells
(DC) and assessed alloactivation in the presence or absence of the
MEK inhibitor U0126. U0126-treated CD4+ and CD8 +T cells
were 60-70% less activated than DMSO-treated cells, as assessed
both by CD38 upregulation and CFSE dilution. Nextwedetermined
whether U0126 selectively suppresses cytokine production in a stage-
dependent manner. We stimulated PBMC from healthy subjects
(n5 7) with SEB in the presence of U0126 and measured IL-2,
IFNg and TNFa production in T cell maturation subsets. In
CD4 +T cells, both IL-2 and TNFa production were significantly
more suppressed in naive and early memory cells (Table 1). In CD8+
cells, we similarly saw reductions in IFNg and TNFa production fol-
lowing MEK inhibition (Table 1). Preliminary experiments also sug-
gest that U0126 only minimally suppresses of CMV pp65-specific T
cells from healthy subjects (n5 3), although additional confirmation
is needed. These data demonstrate thatMEK inhibition preferentially
inhibits naive and early memory cells critical for GVHD initiation
while sparing late-memory CMV-specific cells, providing the basis
for more selective clinical strategies for GVHD inhibition.Mean percent reduction in cytokine production in response to
U0126 (n5 7)
Cell Cytokine N M1 M2 M3
CD41 IL-2 79% 56% 50% **
CD41 TNFa 87% 62% 48% **
CD81 IFNg 58% 30% 15% 0%
CD81 TNFa 70% 55% 38% 5%
*all P\0.05 for CD4: N vs. M1, M1 vs. M2, CD8: N vs. M1, M1 vs. M2,
M2 vs. M3.
**M3 cells are not significantly present in CD41 cells.392
STATINS INHIBIT THE ANTIGEN-PRESENTING FUNCTION OF HUMAN B
CELLS
Shimabukuro-Vornhagen, A.1,2, Zoghi, S.2, Liebig, T.2, von Bergwelt-
Baildon, M.1,2 1University Hospital of Cologne, Germany; 2University
Hospital of Cologne, Germany
Statins are lipid-lowering drugs that reduce cholesterol produc-
tion by inhibiting HMG-CoA-reductase the rate-limiting enzymeof the mevalonate pathway. Besides their lipid-lowering effect statins
possess potent immunomodulatory activity. Apart from T cells sev-
eral other immune cells, including B cells, have been shown to be in-
volved in the pathophysiology of graft-versus-host disease (GVHD).
We conducted a expression analysis which showed that the genes of
the mevalonate pathway were upregulated following activation of
human B cells via CD40. Therefore we tested whether statins could
inhibit the activation and antigen-presenting function of B cells as
well as their ability to stimulate the proliferation of allogeneic T
cells. Addition of simvastatin led to a dose-dependent inhibition of
B cell activation and proliferation following stimulation via CD40.
The upregulation of important costimulatory molecules such as
CD80 and CD86 as well as MHC class II was significantly reduced
when simvastatin was added to co-cultures of purified human B cells
with CD40 ligand-expressing fibroblasts. As a consequence the pro-
liferation of allogeneic T cells in response to simvastatin-treated
CD40-activated B cells was significantly decreased compared to un-
treated controls. Addition of atorvastatin had similar effects on
CD40-activated B cells. Surprisingly, the hydrophilic statin pravas-
tatin had no significant effects on B cell activation and antigen-pre-
senting function. Importantly, the doses of simvastatin that were
required for inhibition of the antigen presenting function of B cells
were at least one order of magnitude lower than those required to in-
hibit T cell activation and proliferation induced by anti-CD3/anti-
CD28-coated beads. These results therefore suggest that inhibition
of antigen-presenting cells is an important mechanism by which sta-
tins mediate their immunomodulatory effects. Furthermore, the
observation that pravastatin had no significant effect on antigen-
presenting function has important clinical implications and indicates
that hydrophilic statins like simvastatin should be prefered in future
clinical trials assessing the impact of statins on GVHD.
In summary, our findings demonstrate that statins are promising
immunodulatory agents for the prevention and treatment of
GVHD.This notion is supported by the results of recent clinial trials
which found a reduction in acute and chronic GVHD in patients
which were treated with statins.393
PRIMARY HUMAN ACUTE MYELOID LEUKEMIA STEM CELLS SHOW
REDUCED SENSITIVITY TO NATURAL KILLER CELL-MEDIATED KILLING
Gill, S.1, Majeti, R.2, Bowler, M.1, Negrin, R.S.1 1Stanford University,
Stanford, CA; 2Stanford University, Palo Alto, CA
Introduction:Relapse after initial response to treatment of acute
myeloid leukemia (AML) may be due to the persistence of leu-
kemia stem cells (LSC), which show resistance to chemotherapy.
Currently, the optimal approach to the targeting of LSC is un-
known. In this study, we sought to investigate the potential
graft-versus-leukemia effect of allogeneic natural killer (NK)
cells on AML LSC using immunophenotypic and functional
studies.
Methods: Samples were obtained from the peripheral blood of 11
newly diagnosed patients with AML, under an institutional re-
view board-approved protocol. AML sub-populations were de-
fined based on expression of CD34 and CD38. Initial analysis
included cytofluorometric immunophenotyping of the NK recep-
tor ligand molecules MICA/B, CD112, CD155, HLA-E, MHC
class I, CD48, Fas, DR4 and DR5 in the different AML sub-
populations. Of the 11 samples analysed, four contained an
indentifiable distinct CD34 + CD38- population (defined immu-
nophenotypically as LSC compared to the more mature popula-
tion with the phenotype of CD34 + CD38+), and these were
selected for functional studies. Subpopulations were separated us-
ing fluorescence-activated cell sorting and incubated with effec-
tors (interleukin-2 stimulated purified allogeneic NK cells and
the NK-92 cell line).
Results: Analysis of NK receptor ligands revealed non-significantly
lower expression amongst the LSC population of the activating
NKG2D ligands MICA/B (mean 10.9% +- 2.0 vs 34.7% +- 11.8,
p5 0.16) as well as of the 2B4 ligand CD48 (mean 0.5% +- 0.2 vs
10.3% +- 4.9, p5 0.15). Using a panel of four different effectors,
the putative LSC population and the non-LSC blast population
were found to respond differentially to NK cell-mediated cytototox-
icity, with caspase activation (as a measure of apoptosis) in the blast
